Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor
- 19 February 2014
- journal article
- research article
- Published by Elsevier in Journal of Surgical Research
- Vol. 190 (1) , 111-118
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Active Targeting Using HER‐2‐Affibody‐Conjugated Nanoparticles Enabled Sensitive and Specific Imaging of Orthotopic HER‐2 Positive Ovarian TumorsSmall, 2013
- Targeted Drug Delivery Systems Mediated by a Novel Peptide in Breast Cancer Therapy and ImagingPLOS ONE, 2013
- Folic acid-tethered Pep-1 peptide-conjugated liposomal nanocarrier for enhanced intracellular drug delivery to cancer cells: conformational characterization and in vitro cellular uptake evaluationInternational Journal of Nanomedicine, 2013
- Therapy for metastatic melanoma: the past, present, and futureBMC Medicine, 2012
- Selective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticlesInternational Journal of Nanomedicine, 2012
- Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanomaBritish Journal of Cancer, 2011
- Mechanism-Based Tumor-Targeting Drug Delivery System. Validation of Efficient Vitamin Receptor-Mediated Endocytosis and Drug ReleaseBioconjugate Chemistry, 2010
- Anti-EMMPRIN Monoclonal Antibody as a Novel Agent for Therapy of Head and Neck CancerClinical Cancer Research, 2009
- Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2008
- Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in ratsJournal of Controlled Release, 2008